中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (7): 538-542.doi: 10.12144/zgmfskin202507538

• 综述 • 上一篇    

大疱性类天疱疮治疗进展

刘明月1,谭姝慧1,章哲1,聂振华2   

  1. 1 天津中医药大学，天津，301617；2 天津市中医药研究院附属医院，天津，300120
  • 出版日期:2025-07-15 发布日期:2025-07-07

Update of the treatment for bullous pemphigoid

LIU Mingyue1, TAN Shuhui1, ZHANG Zhe1, NIE Zhenhua2   

  1. 1 Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; 2 Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine， Tianjin 300120, China
  • Online:2025-07-15 Published:2025-07-07

PDF (PC)

20

摘要： 大疱性类天疱疮(bullous pemphigoid,BP)是一种常见的自身免疫性表皮下大疱性皮肤病，好发于老年人，有较高的复发率及死亡率。近年来，针对不同靶点的生物制剂、补体抑制剂、Janus激酶（JAK）抑制剂的出现，为BP治疗提供了更多的治疗选择。本文对BP新的治疗方法进行综述，为临床应用提供借鉴。

关键词: 大疱性类天疱疮, 生物制剂, JAK抑制剂

Abstract: Bullous pemphigoid （BP） is a common autoimmune subepidermal bullous skin disease that predominantly affects the elderly with a high recurrence rate and mortality. In recent years, the emergence of biological agents, complement inhibitors and Janus kinase (JAK) inhibitors targeting different targets has provided more therapeutic options for BP. This paper reviews the new treatments for BP to provide reference for clinical application.

Key words: bullous pemphigoid, biological agents, JAK inhibitors